Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

NCT07486869 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT07486869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2026
Completion date
July 31, 2027
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, dermatomyositis sine myositis, dermatomyositis with myopathy, dermatomyositis with organ involvement, dermatomyositis with respiratory involvement, interstitial lung disease, interstitial lung disease due to connective tissue disease (disorder)